Camurus  has announced revised full year 2020 guidance for the company’s revenue and product sales. Camurus’ guidance for net revenue is increased to SEK 340–380 million from SEK 290–330 million

The Board of Directors of BioInvent International has resolved to issue a directed share issue to Swedish and international institutional investors. Investors in the Directed Share Issue are a number

Ilya Pharma has secured a total of 5.3 million EUR in funding from the European Innovation Council (EIC) Accelerator program of blended financing. The funds will enable Ilya Pharma to

Ilya Pharma is one of ten life science companies selected this year for Springboard Enterprises’ Health Innovation Hub: Life Science. The company joins over 800 experienced “been there, run that”

The Board of Directors of Xbrane Biopharma has successfully completed a directed issue of 3,853,799 shares corresponding to approximately SEK 146 million before costs related to the transaction. The subscription

BioInvent International has announced the presentation of promising new data on its anti-tumor necrosis factor receptor 2 (TNFR2) program at the American Association for Cancer Research (AACR) Annual Meeting. The

Xbrane Biopharma and its co-development partner STADA have entered into an exclusive licensing agreement with Bausch + Lomb to commercialize Xlucane, a Lucentis (ranibizumab) biosimilar candidate, in the United States

Swedish biotechnology start-up Cartana has announced the appointment of Mårten Winge as CEO. A spin-out from the SciLifeLab, Cartana has launched a new spatial cell type mapping service and reagent

Xbrane Biopharma strengthens its management team to better equip the company for commercialization of its biosimilars and Paolo Sarmientos steps out of the management team. Xbrane Biopharma is advancing its

The European Union’s Horizon 2020 funding program has confirmed support for six pilot European Human Cell Atlas projects designed to contribute to the international Human Cell Atlas initiative (HCA) with